BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17671729)

  • 1. Adenoviral B7-H3 therapy induces tumor specific immune responses and reduces secondary metastasis in a murine model of colon cancer.
    Lupu CM; Eisenbach C; Lupu AD; Kuefner MA; Hoyler B; Stremmel W; Encke J
    Oncol Rep; 2007 Sep; 18(3):745-8. PubMed ID: 17671729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.
    Hull GW; Mccurdy MA; Nasu Y; Bangma CH; Yang G; Shimura S; Lee HM; Wang J; Albani J; Ebara S; Sato T; Timme TL; Thompson TC
    Clin Cancer Res; 2000 Oct; 6(10):4101-9. PubMed ID: 11051263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity.
    Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J
    Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
    Xiang J; Chen Y; Moyana T
    Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.
    Odaka M; Sterman DH; Wiewrodt R; Zhang Y; Kiefer M; Amin KM; Gao GP; Wilson JM; Barsoum J; Kaiser LR; Albelda SM
    Cancer Res; 2001 Aug; 61(16):6201-12. PubMed ID: 11507073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
    Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
    J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse B7-H3 induces antitumor immunity.
    Sun X; Vale M; Leung E; Kanwar JR; Gupta R; Krissansen GW
    Gene Ther; 2003 Sep; 10(20):1728-34. PubMed ID: 12939639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
    Saika T; Satoh T; Kusaka N; Ebara S; Mouraviev VB; Timme TL; Thompson TC
    Cancer Gene Ther; 2004 May; 11(5):317-24. PubMed ID: 15044961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery.
    Pan PY; Li Y; Li Q; Gu P; Martinet O; Thung S; Chen SH
    Cancer Immunol Immunother; 2004 Jan; 53(1):17-25. PubMed ID: 12955480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer].
    Yang Q; Yang G; Wei L; Jia F; Wu M; Guo Y
    Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):775-9. PubMed ID: 12126551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene.
    Ramesh R; Munshi A; Abboud CN; Marrogi AJ; Freeman SM
    Cancer Gene Ther; 1996; 3(6):373-84. PubMed ID: 8988840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.
    Chen SH; Pham-Nguyen KB; Martinet O; Huang Y; Yang W; Thung SN; Chen L; Mittler R; Woo SL
    Mol Ther; 2000 Jul; 2(1):39-46. PubMed ID: 10899826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.